Promising Growth and Diversification Drive Buy Rating for Crispr Therapeutics AG

William Blair analyst Sami Corwin has reiterated their bullish stance on CRSP stock, giving a Buy rating on May 21.

Sami Corwin has given his Buy rating due to a combination of factors that highlight Crispr Therapeutics AG’s promising future. The company is poised for significant growth with the ongoing launch of Casgevy, which is expected to become a major player in the biotechnology sector by 2025. This growth is supported by several key milestones anticipated in the next year, which could greatly expand the company’s pipeline.
Furthermore, Crispr Therapeutics is not only focusing on Casgevy but is also diversifying its pipeline to include areas such as immuno-oncology, autoimmune diseases, and cardiovascular indications. The company has already reported promising data from its in vivo gene-editing program, CTX310, and is on track to share more clinical data from other assets in the near future. These developments, coupled with strategic partnerships and a growing global market, underpin the Buy rating.

In another report released on May 21, Citizens JMP also reiterated a Buy rating on the stock with a $86.00 price target.